Published 07/13/2026
Key Takeaways
- Long-term extension data from APOLLOE4 suggest sustained CDR-SB separation with valiltramiprosate in APOE4/4 participants with MCI due to early Alzheimer disease.
- Participants who received active treatment in both the core and extension periods had less CDR-SB decline than those who started treatment after placebo.
- No symptomatic ARIA events were reported in the long-term extension analysis.
Valiltramiprosate/ALZ-801 (Alzheon, Framingham, MA), an investigational oral amyloid-oligomer inhibitor, was associated with sustained clinical separation over approximately 2.5 years in APOE4/4 homozygous participants with mild cognitive impairment (MCI) due to early Alzheimer disease (AD), according to long-term extension results from the phase 3 APOLLOE4 study (NCT04770220) presented at the Alzheimer’s Association International Conference (AAIC) 2026.
